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Abstract
Purpose: Current guidelines recommend stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung
cancer (NSCLC) in medically inoperable patients. There are excellent outcome and toxicity data for SBRT of
peripheral lung tumors. However, the discussion on SBRT for centrally located tumors is controversial. This study
evaluated current clinical practice regarding SBRT of centrally located lung tumors, to identify common
fractionation schedules and commonly accepted contraindications for SBRT.
Methods: A questionnaire consisting of two parts was introduced at the annual meeting of the DEGRO
working group on stereotactic radiotherapy, representing centers in Germany and Switzerland. The first part
of the questionnaire covered general information about the centers, whereas the second part specifically
addressed SBRT of centrally located lung tumors, using case examples of nine primary NSCLC patients.
Reconstructions of a contrast enhanced CT, as well as PET-Imaging for each case were demonstrated to
the participants.
Results: Twenty-six centers participated in the meeting. The majority was academic (73%), participated in
interdisciplinary thoracic oncology tumorboards (88%) and offered SBRT for lung tumors (96%). Two centers
questioned the indication of SBRT for central lung tumors because of lack of evidence. The majority of
centers had experience in SBRT for central lung tumors (88%) and half of the centers reported more than
ten cases treated during a median period of five years. Most fractionation schedules used PTV encompassing
doses of 48–60 Gy in eight fractions with maximum doses of 125–150%.
A clear indication for SBRT treatment was seen by more than 85% of centers in three of the nine patients in
whom tumors were small and not closer than 2 cm to the main bronchus. Prior pneumonectomy or
immediate adjacency to hilar/mediastinal structures were not considered as contraindications for SBRT. In
cases where the tumor exceeded 4 cm in diameter or was located closer than 4 cm to the carina 50–80%
of centers saw an indication for SBRT. One case, with a 7 cm tumor reaching to the carina would have
been treated with SBRT only by one center.
Conclusion: Within DEGRO working group on stereotactic radiotherapy, SBRT for small (<4 cm) early stage
NSCLC is a common indication, if the minimal distance to the main bronchi is at least 2 cm. The controversy
on the treatment of larger and more central tumors will hopefully be solved by ongoing prospective clinical
trials.
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Background
Malignant neoplasms of the lung are the most fre-
quent cause of cancer-related death in the world
with approximately 350,000 deaths in Europe and 1.6
million deaths worldwide in 2012 [1–3]. Although
the overall prognosis of non-small cell lung cancer
(NSCLC) is poor, early stage without regional or
metastatic spread can be cured by local treatment.
The combination of future screening programs on
the basis of computed tomography (CT) and an
aging population will most likely increase the inci-
dence of early stage lung cancer, especially in elderly
patients [4, 5].
Surgical lobectomy plus mediastinal lymph node
dissection is the standard treatment for early stage
NSCLC. However, the increasing number of elderly pa-
tients with comorbidities demonstrates the need for
less-invasive therapies [6]. Stereotactic body radiother-
apy (SBRT) for peripherally located early stage lung
cancer has recently emerged as a safe and non-invasive
alternative to surgical resection with equivalent rates of
local tumor control, and has been established as stand-
ard of care for inoperable tumors in specialized centers
[7–9].
However, centrally located lung tumors represent a
challenge for both surgical treatment and SBRT. Cen-
tral tumors may more likely require extensive surgery
like pneumonectomy, which bears the risk of inferior
outcome or inoperability [10, 11]. Likewise, there is evi-
dence that SBRT of central tumors has an increased
risk of severe toxicity, which may be up to 11 times
higher than in peripheral tumors [12]. Overall, pro-
spective data on SBRT of central tumors is sparse, but
presently recruiting clinical trials will prospectively as-
sess long term benefits and risks of SBRT for this pa-
tient population in order to generate solid evidence on
local control and toxicity [13, 14].
Unfortunately, “central location” is not consistently
defined in recent prospective trials, as shown in the
following examples: (1) RTOG 0236: a tumor within
2 cm to the proximal bronchial tree (PBT), which
was described as the distal 2 cm of the trachea, car-
ina, main bronchi and named major lobar bronchi up
to their first bifurcation (i.e. upper and lower lobe
bronchi, intermedius bronchus, lingular bronchus)
[15, 16]; (2) IASLC recommendation: a tumor within
2 cm to any mediastinal critical structure, including
the bronchial tree, esophagus, heart, major vessels,
spinal cord, brachial plexus, phrenic and recurrent la-
ryngeal nerve [17]; (3) RTOG 0813: a tumor within
2 cm to the PBT or touching the mediastinal pleura
[18]; some authors further enlarged the zone by
tumors within 6 mm to the pericardium or 1 cm
around the mediastinum [19, 20].
Furthermore, SBRT in daily routine follows not only
published evidence but also depends on the physician’s
experience and expertise, resulting in a variety of treat-
ment schedules. At present, it is unknown whether
SBRT can be applied to all centrally located tumors or
whether there are locations which are too close to crit-
ical organs at risk.
Therefore, this study evaluated the patterns of current
clinical practice of SBRT for centrally located lung tu-
mors in 26 German and Swiss centers with the aim to
identify common fractionation schedules and commonly
accepted contraindications.
Methods
A questionnaire consisting of two parts was presented
to representatives of 26 centers in Germany (n = 25)
and Switzerland (n = 1) during the annual meeting of
the DEGRO working group on stereotactic radiother-
apy. The first part of the questionnaire addressed
general information about the centers such as type
(academic vs non-academic), institution size, experi-
ence and treatment specifications regarding lung
SBRT in general.
In the second part of the questionnaire, the partici-
pants were shown nine cases of centrally located pri-
mary NSCLC (cT2-4 cN0 cM0) and were asked to
determine if SBRT was indicated and which fraction-
ation schedule they would suggest. Furthermore, they
were asked to provide reasons if they rejected SBRT in
a specific case and to suggest alternative treatments. All
presented cases originated from four different academic
centers (UniversitätsSpital Zürich, Universitätsklinikum
Würzburg, Universitätsklinikum Heidelberg, Klinikum
der Universität München) and were consequently anon-
ymized. The survey participants were shown axial, sagittal
and coronal reconstructions of a contrast-enhanced 3D-
CT of the lungs in combination with fluordeoxyglucose
positron emission tomography (FDG-PET) imaging if
available. The medical history for all cases was assumed
to be identical: a 75-year-old male, active smoker with
25 pack-years and relevant comorbidities of chronic
obstructive pulmonary disease (FEV1 = 1 l/s), diabetes
type 2, hypertension and congestive heart disease after
coronary dilatation because of unstable angina pectoris
five years ago.
Results
The majority of the participating centers were academic
(n = 19), participated in interdisciplinary thoracic oncol-
ogy tumorboards (n = 23) and practiced SBRT for lung
tumors as standard (n = 25, see Table 1). Two centers
questioned the suitability of SBRT for central lung tu-
mors because of lack of evidence and therefore did not
practice it. The majority of centers had experience in
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SBRT for central lung tumors. Thirteen centers referred
more than ten treated cases during a median period of
five years, whereas the remaining ten centers reported
less than ten treated cases within a median period of
three years.
A FDG-PET scan was an essential component of
the staging procedure in each center and, when
reasonable, was frequently used for target volume def-
inition (n = 21, 81%). A 4D-CT scan was standard in
69% for treatment planning (n = 18). Image guidance
by cone-beam CT or by another system was practiced
by all centers. Most centers used eight fractions of 6–
7.5 Gy prescribed to the 65-90% isodose surrounding
the planning target volume (PTV) as their standard
fractionation schedule for SBRT of peripherally and
central lung tumors. About one quarter of the centers
recommended three fractions of 12.5 Gy prescribed to
an isodose line between 60-67%. No center used sin-
gle fraction regimens as standard. Center characteris-
tics and treatment standards are summarized in
Tables 1 and 2, respectively.
The following figures describe the tumor location
and treatment recommendations for the nine cases. In
the coronal (left-right), sagittal (anterior-posterior) and
longitudinal (superior–inferior) axis the longest tumor
diameters were measured. Furthermore, the maximum
tumor diameter as well as the minimal distance to the
carina, the mediastinum and the main bronchi are
provided.
Case 1
Tumor characteristics of case 1. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body radio-
therapy, RT Radiotherapy, RCT Radiochemotherapy
Tumor location: Within left upper lobe, between left pulmonary artery
and left upper lobe bronchus
Shortest
distance
to
mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest
distance
to main
bronchus
[cm]
Size
(cor/sag/long)
[cm]
Maximum
diameter
[cm]
0 3.8 0 1.7/1.6/1.8 1.9
SBRT
accepted
Most
frequently
used
fractionation
Second most
frequently
used
fractionation
Mean
number
of fractions
Mean dose
per fraction
[Gy]
21 (81%) 8 × 7.5 Gy @
65–95%
8 × 6 Gy @
65%
7.1 7.6
SBRT
declined
Reasons to
decline SBRT
Most frequently
recommended alternative
treatment
5 (19%) Risk to central
airways
Conventionally
fractionated RT to 70Gy
Table 1 Individual center characteristics
General questionnaire items
Center type Academic = 19
Public = 4
Private = 2
Non specified = 1
Median number of linear accelerators 3 (range 2 – 7)
Regular participation in thoracic
oncology tumorboard
88%
Overall experience in SBRT of the
centrally located NSCLC
0 cases = 3
<10 cases = 10
>10 cases = 13
Duration of SBRT experience 5 years (range: 1 – 15)
General treatment items
Imaging for target volume definition 4D-CT = 18
PET-CT = 21
Image guidance CBCT = 24
TOMO = 2
Other = 2
Patient immobilization system Body Fix/Frame = 11
vacuum matrass = 7
unknown = 7
Abdominal compression 3
Table 2 Most common standard fractionation schedules for
SBRT of lung tumors in general
Fractions Dose Isodose line
surrounding PTV
Number
of centers
Percentage
of centers
3 12.5 60–67% 6 26%
5 7 65–80% 2 9%
5 8 65% 1 4%
6 8 - 1 4%
8 6 65–80% 3 13%
8 7.5 70–90% 9 39%
10 6 90% 1 4%
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Case 2
Tumor characteristics of case 2. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body
radiotherapy, RT Radiotherapy, RCT Radiochemotherapy
Tumor characteristics of case 3. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body
radiotherapy, RT Radiotherapy, RCT Radiochemotherapy
Tumor location: Within left lower lobe, adjacent to main bronchus
Shortest distance
to mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest
distance
to main
bronchus [cm]
Size
(cor/sag/
long) [cm]
Maximum
diameter
[cm]
0 4.4 0 2.3/3.2/2.1 4.9
SBRT accepted Most
frequently
used
fractionation
Second most
frequently
used
fractionation
Mean
number
of fractions
Mean
dose per
fraction
[Gy]
20 (77%) 8 × 7.5 Gy @
65–90%
5 × 7 Gy @
65%
7.0 7.6
SBRT declined Reasons to
decline SBRT
Most frequently
recommended
alternative treatment
6 (23%) Size, risk for left
main bronchus
Conventionally
fractionated RT
to 66-70Gy
Tumor location: Centrally located within the right hilus
Shortest distance
to mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest
distance to
main bronchus
[cm]
Size (cor/
sag/long)
[cm]
Maximum
diameter
[cm]
0 2.5 0 3.2/3.5/3.2 3.5
SBRT accepted Most
frequently
used
fractionation
Second most
frequently used
fractionation
Mean
number of
fractions
Mean
dose per
fraction [Gy]
14 (54%) 8 × 7.5 Gy
@ 80–90%
5 × 8 Gy
@ 65%
7.5 6.3
SBRT declined Reasons to decline SBRT Most frequently
recommended
alternative treatment
12 (46%) Risk for right main bronchus Conventionally
fractionated
RCT to 66 Gy
Case 3 Tumor location: large tumor reaching to carina, infiltrating the upper lobe
bronchus and the main bronchus
Shortest
distance to
mediastinum [cm]
Shortest
distance to
carina [cm]
Shortest distance
to main
bronchus [cm]
Size (cor/
sag/long)
[cm]
Maximum
diameter
[cm]
0 0 0 6.8/5.7/6.4 7.6
SBRT accepted Most
frequently
used
fractionation
Second most
frequently used
fractionation
Mean
number
of
fractions
Mean
dose per
fraction
[Gy]
1 (4%) 8 × 5 Gy - - -
SBRT declined Reasons to decline SBRT Most frequently
recommended
alternative treatment
25 (96%) Size, risk to central airways Conventionally
fractionated RCT to
66Gy; Palliative RT
30 Gy/10 fr.
Case 4
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Tumor characteristics of case 4. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body radio-
therapy, RT Radiotherapy, RCT Radiochemotherapy
Tumor characteristics of case 5. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body radio-
therapy, RT Radiotherapy, RCT Radiochemotherapy
Tumor characteristics of case 6. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body radio-
therapy, RT Radiotherapy, RCT Radiochemotherapy
Case 7
Tumor location: centrally localized, next to right lower bronchus after
pneumonectomy of the left lung
Shortest
distance to
mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest distance
to main bronchus
[cm]
Size (cor/
sag/long)
[cm]
Maximum
diameter
[cm]
3.5 7.8 1.9 3.5/2.8/2.5 3.5
SBRT accepted Most
frequently
used
fractionation
Second most
frequently used
fractionation
Mean
number of
fractions
Mean dose
per fraction
[Gy]
22 (88%) 8 × 7.5 Gy @
65–90%
3 × 15 Gy @ 65% 6.0 9.4
SBRT declined Reasons to decline SBRT Most frequently
recommended
alternative treatment
3 (12%) Localization too central Conventionally
fractionated RT
Case 5
Case 6
Tumor location: right lower lobe, adjacent to the esophagus
Shortest
distance to
mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest distance
to main
bronchus [cm]
Size (cor/
sag/long)
[cm]
Maximum
diameter
[cm]
0 7.5 2.2 2.5/2.3/1.8 3.7
SBRT accepted Most
frequently
used
fractionation
Second most
frequently used
fractionation
Mean
number of
fractions
Mean dose
per
fraction
[Gy]
22 (88%) 8 x 7.5 Gy @
65-90%
3 x 13.5/12,5 Gy
@ 65%
6.8 8.5
SBRT declined Reasons to decline SBRT Most frequently
recommended
alternative treatment
3 (12%) Localization too central, risk to
esophagus
Surgery, conventionally
fractionated RT with
small margins
Tumor location: Left upper lobe, Adjacent to the mediastinum at the height
of the aortic arch
Shortest
distance to
mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest distance
to main
bronchus [cm]
Size (cor/
sag/long)
[cm]
Maximum
diameter
[cm]
0 6.5 5 2.0/3.9/4.7 4.7
SBRT accepted Most
frequently
used
fractionation
Second most
frequently used
fractionation
Mean
number of
fractions
Mean dose
per
fraction
[Gy]
21 (81%) 8 x 7.5 Gy @
65-80%
8 x 6 Gy @ 65-
80%
6.8 8.9
SBRT declined Reasons to decline SBRT Most frequently
recommended
alternative treatment
5 (19%) Risk for aorta Conventionally
fractionated RT +/−
chemotherapy
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Tumor characteristics of case 7. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body radio-
therapy, RT Radiotherapy, RCT Radiochemotherapy
Case 8
Tumor characteristics of case 8. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body radio-
therapy, RT Radiotherapy, RCT Radiochemotherapy
Tumor characteristics of case 9. Abbreviations: cor coronal,
sag sagittal, long longitudinal, SBRT Stereotactic body radio-
therapy, RT Radiotherapy, RCT Radiochemotherapy
Discussion
This survey demonstrates the current controversy re-
garding indications and contraindications for SBRT in
central lung tumors, with a clear tendency towards the
use of risk-adapted irradiation schedules. We categorized
cases according to their level of acceptance (see Table 3)
and identified three distinct decision criteria for SBRT:
tumor size, exact location within the central zone and
relation to the surrounding critical organs at risk, par-
ticularly the central airways.
Tumor location: Large in size, right lower lobe, right after ramification of
intermediate bronchi
Shortest
distance to
mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest distance
to main bronchus
[cm]
Size (cor/
sag/long)
[cm]
Maximum
diameter
[cm]
0 3.6 0.5 4.5/5.6/5.0 5.7
SBRT accepted Most
frequently
used
fractionation
Second most
frequently used
fractionation
Mean
number of
fractions
Mean dose
per fraction
[Gy]
16 (62%) 8 x 7.5 Gy @
65-85%
5 x 7 Gy @ 60-
65%
7.3 7.6
SBRT declined Reasons to decline SBRT Most frequently
recommended
alternative treatment
10 (38%) Size Conventionally
fractionated RT, Palliative
hypofractionated RT
Case 9
Tumor location: left lower lobe, adjacent to Aorta
Shortest
distance to
mediastinum
[cm]
Shortest
distance to
carina [cm]
Shortest
distance
to main
bronchus
2[cm]
Size (cor/
sag/long)
[cm]
Maximum
diameter
[cm]
0 8.3 4.6 1.8/1.2/1.5 2.1
SBRT
accepted
Most
frequently
used
fractionation
Second most
frequently used
fractionation
Mean
number
of
fractions
Mean dose
per
fraction
[Gy]
22 (85%) 8 x 7.5
Gy @ 65-90%
3 x 12,5 Gy @
60-65%
6.6 8.7
SBRT
declined
Reasons
to decline SBRT
Most frequently
recommended
alternative treatment
4 (15%) Risk for aorta Palliative RT, surgery
Table 3 Cases grouped according to their level of acceptance
Level of acceptance High (>85%) Intermediate Low (<50%)
Case Nr. 5, 6, 9 1, 2, 3, 7, 8 4
Most critical organ
at risk
Main bronchus,
esophagus, aorta
Main bronchus,
upper lobe
bronchus, aorta
Main
bronchus
Maximal tumor
diameter
(range/median)
2.1–3.7 cm/
3.5 cm
1.9–5.7 cm/
4.7 cm
7.6 cm
Minimal distance
to carina
(range/median)
7.5–8.3 cm/
7.8 cm
2.5–6.5 cm/
3.8 cm
0 cm
Minimal distance
to main bronchus
(range/median)
1.9–4.6 cm/
2.2 cm
0–0.5 cm/
0 cm
0 cm
Alternative
treatment
RT 70 Gy/
35 fr.
RCT: 66 Gy/
33 fr.
RT: 30 Gy/10
fr. or RCT:
66 Gy/33 fr.
Most frequently
stereotactic
fractionation
60 Gy/8 fr. 60 Gy/8 fr. 40 Gy/8 fr.
Second most
frequently stereotactic
fractionation
37,5–50 Gy/3 fr. 35–40 Gy/5 fr.
48 Gy/8 fr.
-
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We observed a high agreement (>85%) to perform
SBRT despite central location for tumors with a max-
imal diameter of up to 4 cm, a minimal distance to the
main bronchi of about 2 cm and without infiltration of
lobar bronchi.
These tumors were located within the central zone as
defined in the RTOG 0813 trial, but mainly distally with
regard to the original definition by Timmerman et al.
[12, 18]. The latter was used in the RTOG 0236 trial
where the tumor was required to have a distance of at
least 2 cm to the PBT, which was defined as the trachea,
carina, main bronchi, and named major lobar bronchi up
to their first bifurcation (i.e. upper and lower lobe bronchi,
intermedius bronchus, lingular bronchus) [15, 16]. RTOG
0813 included tumors within 2 cm to the PBT or touching
the mediastinum [18]. Furthermore, case 5 showed that
prior pneumonectomy was not considered as a contraindi-
cation even in centrally located tumors, offering these
high-risk patients a potentially curative treatment option.
Lung tumors which had only an intermediate level of
acceptance for SBRT (54-81%) were located within the
central zone as defined in RTOG 0813. SBRT was contra-
indicated by several centers due to close proximity to the
central airways (case 1–3), particularly when the tumor
was directly located at the hilus (case 2). These cases met
the criteria of “ultra-central” tumors which can be defined
in two ways: Either the gross tumor volume directly abut-
ted the central airway or the PTV overlapped the trachea
or main bronchi [21, 22].
In contrast, tumors which were immediately adjacent
to the mediastinum and aorta had a higher acceptance
for SBRT of 81-85% (case 3, 7 & 9). A reduced level of
acceptance was also observed for cases where the tumor
diameter exceeded 4 cm (case 2, 4 and 8).
SBRT was rejected by almost all radiation oncologists in
case 4: The tumor exceeded 6 cm in diameter in almost
every dimension and extensively infiltrated the right major
bronchus up to the carina.
Taken together, the most prominent contraindications
for SBRT were proximity to the carina, possible infiltra-
tion of the central airways (tumor immediately adjacent to
the main bronchus) and tumor size beyond 4 cm. Each of
the three criteria influenced the decision for or against
SBRT independently, which is demonstrated in Fig. 1.
About half of the centers used schedules of eight frac-
tions as their standard SBRT regimen for central lung
tumors (Table 2), which was also the most frequently used
regimen in the presented cases.
Sixty Gray in eight fractions is a common scheme for
centrally located lung tumors propagated in particular
by the group from VU University Medical Center
Amsterdam/Netherlands [20, 23, 24]. The latest update
of their series retrospectively compared 80 cases of central
SBRT treated with eight fractions of 7.5 Gy (PTV overlap-
ping a 2 cm expansion of the PBT according to RTOG
0813) to 252 cases of peripheral tumors treated with more
escalated regimens [23]. There was no significant differ-
ence in overall survival between both groups and grade
three pulmonary toxicity was observed in 6.4% of cases. In
five cases the PTV overlapped the PBT, but only one pa-
tient developed a bronchial stricture and consecutively
atelectasis. Although no grade four toxicity was described,
six cases (7.5%) were considered to have possible (n = 3)
or likely (n = 3) treatment-related death. Low toxicity rates
of this SBRT regimen were also seen by Taremi et al. and
Guckenberger et al., where two of twenty-two patients
with central tumors developed grade two/three toxicity
after irradiation with 48 Gy in eight fractions prescribed to
the 65% isodose [25, 26]. As these data were not collected
prospectively and patient cohorts show high pulmonary
and cardiologic comorbidity, some toxicities may have es-
caped documentation. Furthermore, there may have been
a low number of patients at risk for specific toxicities
based on the dose distribution.
Five fraction regimens as second most common SBRT
schedules were recommended in the intermediate accept-
ance group. More aggressive three fraction regimens were
recommended only for tumors below 4 cm in size and
distal of the PBT (high acceptance group). No center
chose single-fraction radiotherapy.
It is important to mention that presented CT images
were static. Additional information on tumor motion and
Fig. 1 Criteria influencing the decision for or against SBRT
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corresponding organs at risk certainly would have influ-
enced the decision whether and how SBRT would have
been carried out. Obviously, this survey does not include
the results of patient-specific interdisciplinary case discus-
sion and counseling. Furthermore, not all participants
completed the whole questionnaire. Due to the small
number of participants the statistical analysis is descriptive
rather than inferential.
Conclusion
This survey showed a high level of acceptance of SBRT
for selected cases with small centrally located tumors
and minimal distance to the main bronchus of at least
2 cm. Apart from tumor size, the exact location within
the central zone and the relation to critical organs at risk
were important decision criteria for or against SBRT.
Despite contact or even infiltration of the mediastinum,
SBRT was accepted in small tumors not abutting the
main bronchi. Acceptance of SBRT clearly decreased if
the maximal tumor diameter exceeded 4 cm and the
minimal distance to the main bronchus was below 2 cm.
Secondly, we also observed a risk adaptation of SBRT
fractionation within centrally located tumors, which was
practiced in all participating institutions: higher risk tu-
mors in terms of size and location were treated with a
larger number of SBRT fractions and lower total SBRT
doses. However, the variety of opinions on treatment of
larger and more central tumors reflects the current con-
troversy on this topic, which will hopefully be solved by
running prospective clinical trials.
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